RESEARCH
AI tool identifies rectal cancer patients who benefit from intensified chemoradiotherapyA post-hoc analysis of the phase III ARISTOTLE trial found that higher tumor cell density predicted improved survival in locally advanced rectal cancer patients receiving irinotecan-intensified neoadjuvant chemoradiotherapy; researchers developed a free online tool called Octopath where clinicians can upload biopsy slides for analysis. (The ASCO Post)